Payment overview · 2025
General Payments
$258.25
15 reported records · 8 companies
Healthcare provider profile · identity verified
Anton Dreier, MD
Allopathic & Osteopathic Physicians|Family Medicine · YUKON, OK · NPI 1780112706
Verified facts
What the public records show
CMS Open Payments records show Anton Dreier, MD received $258.25 in general payments during 2025 across 15 reported records.
PFIZER INC. accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $61.62 | 23.9% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $61.11 | 23.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.07 | 12.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.35 | 11.0% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $26.74 | 10.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.89 | 6.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.98 | 5.8% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $14.49 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $258.25 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $61.11 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $45.35 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $42.79 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $42.79 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $42.79 | 2 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $26.74 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 268 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 237 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 48 |
| Lisinopril | Lisinopril | 174 | 47 |
| Losartan Potassium | Losartan Potassium | 166 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 143 | 47 |
| Trazodone Hcl | Trazodone Hcl | 137 | 36 |
| Gabapentin | Gabapentin | 136 | 42 |
| Omeprazole | Omeprazole | 127 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 29 |
| Carvedilol | Carvedilol | 88 | 27 |
| Prednisone | Prednisone | 83 | 61 |
| Azithromycin | Azithromycin | 80 | 64 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 37 |
| Metformin Hcl | Metformin Hcl | 79 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 11 |
| Metformin Hcl Er | Metformin Hcl | 74 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 28 |
| Meloxicam | Meloxicam | 69 | 23 |
| Jardiance | Empagliflozin | 67 | 20 |
| Furosemide | Furosemide | 63 | 25 |
| Alprazolam | Alprazolam | 61 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 15 |
| Ozempic | Semaglutide | 53 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 16 |
| Simvastatin | Simvastatin | 52 | 15 |
| Buspirone Hcl | Buspirone Hcl | 49 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 12 |
| Donepezil Hcl | Donepezil Hcl | 47 | 16 |
| Potassium Chloride | Potassium Chloride | 46 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 11 |
| Eliquis | Apixaban | 44 | 11 |
| Estradiol | Estradiol | 39 | suppressed |
| Allopurinol | Allopurinol | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | 13 |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 25 |
| Sertraline Hcl | Sertraline Hcl | 35 | 13 |
| Tramadol Hcl | Tramadol Hcl | 35 | 17 |
| Glipizide | Glipizide | 34 | 11 |
| Finasteride | Finasteride | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 19 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 22 |
| Valacyclovir | Valacyclovir Hcl | 24 | 15 |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Famotidine | Famotidine | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 16 |
| Baclofen | Baclofen | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 16 |
| Glipizide Er | Glipizide | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Nystatin | Nystatin | 15 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Trueplus Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $258.25 · 15 records | PFIZER INC. | ABRYSVO, BEYFORTUS, COMIRNATY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, NEXPLANON, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, XIFAXAN, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error